Shanghai Henlius Biotech Inc represents a set of core values and corporate philosophy. The company aims to prioritize innovation, quality, and patient-centricity in the field of biotechnology. With a strong focus on research and development, Henlius strives to bring affordable and accessible biopharmaceutical products to improve treatment outcomes for patients worldwide. The company values transparency, integrity, and collaboration, believing in the importance of ethical business practices and maintaining trust with stakeholders. Shanghai Henlius Biotech Inc is committed to continuously advancing medical advancements to benefit global healthcare.

Shanghai Henlius Biotech Inc is primarily present in China, with a focus on the domestic market. Being headquartered in Shanghai, the company strategically operates within the country to leverage the vast opportunities and resources available. With its strong presence in China, Shanghai Henlius Biotech Inc aims to serve the growing demand for biotech products and contribute to the advancement of the healthcare industry in the region. As a leading biopharmaceutical company, Shanghai Henlius Biotech Inc continues to expand its footprint and explore potential collaborations and market opportunities both within China and internationally.

Shanghai Henlius Biotech Inc, a leading biopharmaceutical company, has accomplished significant milestones in its journey. The company has successfully developed and commercialized a portfolio of innovative, high-quality therapeutics, particularly in the field of oncology. Henlius became the first company in China to obtain the Marketing Authorization Approval (MAA) for a monoclonal antibody biosimilar, setting a new benchmark in the industry. With a strong focus on research and development, the company has also achieved remarkable progress in advancing its pipeline products. Shanghai Henlius Biotech Inc continues to make strides in improving patient lives through its cutting-edge biotechnological breakthroughs.

Shanghai Henlius Biotech Inc is a renowned biotechnology company based in Shanghai, China. Established in 2010, the company focuses on the research, development, and commercialization of innovative and high-quality biologics. With a strong commitment to healthcare advancement, Shanghai Henlius Biotech Inc has made significant contributions to the biopharmaceutical industry. The company has a diverse portfolio of products that encompass monoclonal antibodies, biosimilars, and next-generation biotherapeutics. Shanghai Henlius Biotech Inc has also established strategic partnerships with domestic and international pharmaceutical companies to enhance its global presence. With its rich history and dedication to improving patients' lives, Shanghai Henlius Biotech Inc has emerged as a leading player in the biotech industry.

Some of the main competitors of Shanghai Henlius Biotech Inc in the market include domestic pharmaceutical companies such as BeiGene Ltd., Hutchison China MediTech Ltd. (Chi-Med), Jiangsu Hengrui Medicine Co., Ltd., and Innovent Biologics Inc. These companies also operate in the biotechnology sector and compete in areas such as research and development of innovative drugs, manufacturing, and commercialization of biopharmaceutical products.

Shanghai Henlius Biotech Inc is primarily active in the biotechnology industry.

The business model of Shanghai Henlius Biotech Inc revolves around the development, manufacturing, and commercialization of innovative biopharmaceutical products. As a leading biotech company in China, Henlius focuses on the research and production of high-quality monoclonal antibodies and biosimilars for the treatment of various diseases, including cancer. By utilizing advanced technology and comprehensive quality control systems, Henlius aims to provide cost-effective and accessible healthcare solutions to patients in need. With its strong R&D capabilities and strategic partnerships, Shanghai Henlius Biotech Inc strives to make significant contributions to the biopharmaceutical industry in both domestic and international markets.

Shanghai Henlius Biotech의 P/E 비율은 43.46입니다.

Shanghai Henlius Biotech의 P/S 비율은 7.12입니다.

Shanghai Henlius Biotech에 대한 AlleAktien 품질 점수는 5/10입니다.

예상되는 Shanghai Henlius Biotech 매출은 6.2 조. CNY입니다.

예상되는 Shanghai Henlius Biotech 이익은 1.01 조. CNY입니다.

Shanghai Henlius Biotech Inc is a Chinese company that specializes in the development, production, and marketing of innovative biopharmaceuticals. Henlius has built a comprehensive portfolio of biosimilars, novel antibodies, and cell therapies for the treatment of cancer and other serious diseases. One of Henlius's core businesses is the development and production of biosimilars, which can be introduced to the market as cost-effective alternatives to expensive biopharmaceuticals. The company has a team of over 600 employees, including over 200 scientists, who focus on the research and development of biosimilars. The biosimilars are developed and produced in close collaboration with top international partners such as Pfizer, Boehringer Ingelheim, Accord Healthcare, and others. Another important business area for Henlius is the development of novel antibodies for the treatment of cancer. These antibodies specifically target cancer cells and can mobilize the body's immune system to fight cancer. Henlius has several antibody candidates in clinical development and plans to introduce products soon. Henlius is also involved in cell therapy, an emerging field of biotechnology where a patient's own cells are used for the treatment of diseases. Cell therapy can be used for the treatment of cancer, autoimmune diseases, and other conditions. Henlius has several cell therapy products in clinical development and collaborates closely with leading academics and institutions to advance the development of these products. Henlius's business model is based on the combination of research, development, and production of novel biopharmaceuticals. Henlius has built a comprehensive platform for the development of biosimilars, novel antibodies, and cell therapy products, supported by experienced scientists and a dedicated leadership team. Henlius's products have the potential to improve the lives of millions of patients worldwide and make the company a key player in the biopharmaceutical market. Overall, Henlius has developed a wide range of products and services to meet the needs of patients and the market. The company relies on collaboration with leading partners and institutions to accelerate the development and production of biopharmaceuticals. Henlius has ambitious plans for the future and is likely to play a significant role in the development of biosimilars, novel antibodies, and cell therapies.

Shanghai Henlius Biotech은(는) 연간 번의 배당을 통해 0 CNY의 배당금을 지급합니다.

Shanghai Henlius Biotech의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Shanghai Henlius Biotech의 ISIN은 CNE100003N76입니다.

Shanghai Henlius Biotech의 티커는 2696.HK입니다.

지난 12개월 동안 Shanghai Henlius Biotech은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Shanghai Henlius Biotech은(는) 0 CNY의 배당금을 지급할 것으로 예상됩니다.

Shanghai Henlius Biotech의 현재 배당 수익률은 입니다.

Shanghai Henlius Biotech은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Shanghai Henlius Biotech은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 CNY의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Shanghai Henlius Biotech은 '건강' 섹터에 속합니다.

Shanghai Henlius Biotech의 마지막 배당금을 0 CNY만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 Shanghai Henlius Biotech는 0 CNY를 배당금으로 지급했습니다.

Shanghai Henlius Biotech의 배당금은 CNY에 지급됩니다.